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Aims: Vancomycin is an important antibiotic for critically ill patients with Gram-
positive bacterial infections. Critically ill patients typically have severely altered path-
ophysiology, which leads to inefficacy or toxicity. Model-informed precision dosing
may aid in optimizing the dose, but prospectively validated tools are not available for
this drug in these patients. We aimed to prospectively validate a population pharma-
cokinetic model for purpose model-informed precision dosing of vancomycin in criti-
cally ill patients.
Methods: We first performed a systematic evaluation of various models on retro-
spectively collected pharmacokinetic data in critically ill patients and then selected
the best performing model. This model was implemented in the Insight Rx clinical
decision support tool and prospectively validated in a multicentre study in critically ill
patients. The predictive performance was obtained as mean prediction error and rela-
tive root mean squared error.
Results: We identified 5 suitable population pharmacokinetic models. The most suit-
able model was carried forward to a prospective validation. We found in a prospec-
tive multicentre study that the selected model could accurately and precisely predict
the vancomycin pharmacokinetics based on a previous measurement, with a mean
prediction error and relative root mean squared error of respectively 8.84% (95%
confidence interval 5.72–11.96%) and 19.8% (95% confidence interval
17.47–22.13%).
Conclusion: Using a systematic approach, with a retrospective evaluation and pro-
spective verification we showed the suitability of a model to predict vancomycin
pharmacokinetics for purposes of model-informed precision dosing in clinical prac-
tice. The presented methodology may serve a generic approach for evaluation of
pharmacometric models for the use of model-informed precision dosing in the clinic.
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1 | INTRODUCTION
Vancomycin is an important antibiotic for critically ill patients with
Gram-positive bacterial infections such as Staphylococcus aureus,
Staphylococcus epidermidis and vancomycin-susceptible Enterococcus.1
Critically ill patients typically have severely altered pathophysiol-
ogy that may lead to clinically relevant changes in pharmacokinetics
(PK) of vancomycin resulting in subtherapeutic or toxic drug expo-
sure2,3 Therapeutic drug monitoring (TDM) can aid in achieving
desired exposure to optimize therapy by adaptations of dosages.
TDM is therefore recommended to guide dosing of vancomycin.4 The
pharmacodynamic index of vancomycin is best described as the
AUC24/MIC (area under the serum concentration–time curve over
24 h divided by the minimum inhibitory concentration) with a target
ratio of ≥400 best correlated with efficacy for infections with Staphy-
lococcus aureus.5 Concentrations of vancomycin below this threshold
are associated with the development of resistance and clinical fail-
ure.1,6 Prolonged high exposure to vancomycin is associated with a
higher likelihood of encountering nephrotoxicity. There is evidence
that TDM significantly increases the rate of clinical efficacy and
decreases the rate of nephrotoxicity in patients treated with vanco-
mycin.7 For practical reasons, trough concentrations are often advised
as a PK target in clinical practice.1
Achieving adequate antibiotic exposure in the critically ill popula-
tion is challenging. The DALI-study showed that only 57% of the
intensive care (IC) unit patients achieved target trough concentrations
(≥15 mg/L)8 and Baptista et al. showed that in patients admitted to
the IC unit with augmented renal clearance only 52% of the patients
reached the therapeutic concentration within 3 days.9
Most clinicians rely on dosing nomograms for dose adjustment of
vancomycin, yet the majority of the published nomograms were
developed in small groups of patients and have not been clinically vali-
dated in external populations.10 Software programs using population
PK models can provide a better alternative to nomograms to optimize
exposure and are capable to more accurately predict dosing require-
ments for the individual patient.11,12
To fully deploy the benefits of model-informed precision dosing
(MIPD), the best possible population PK models that best describe the
local population have to be selected. This should be followed by a pro-
spective validation of PK models. In most cases, prospective validation
of PK models for this purpose is lacking thereby failing to meet above
mentioned requirements.13 The aim of this study was to retrospec-
tively evaluate the performance of existing population PK models for
vancomycin in critically ill patients and, subsequently, prospectively
evaluate the ability of the best performing model to predict vancomy-
cin serum concentrations in this population using the Insight Rx plat-
form (San Francisco, CA, USA).
2 | METHODS
We performed a structured 3-step-approach for our study, consisting
of the following steps:
1 Selection of population PK models of vancomycin in adult patients
from literature
2 Retrospective external evaluation of the predictive performance of
published PK models
3 Prospective evaluation of the selected PK model
2.1 | Selection of population PK models of
vancomycin in adult patients from literature
We performed a systematic literature search in PubMed for all popu-
lation PK studies of vancomycin in adult patients from 2006 until
2016. We combined the following keywords (MeSH and free text) in
our search strategies: vancomycin, pharmacokinetic, adult and popula-
tion pharmacokinetics. Reference lists of identified articles were then
manually screened for additional relevant studies. Furthermore, the
publicly available abstracts from the Population Approach Group
Europe meeting (www.page-meeting.org) were screened.
Models including patients requiring extracorporeal membrane
oxygenation (ECMO) and/or dialysis and models that were based on
<25 patients, were excluded. Publications with no full text available or
focusing on 1 specific patient population (for example haemato-oncol-
ogy, obese, neurosurgical) were also excluded because it is known
that the PK of vancomycin is different in this population compared to
the mixed cohort of IC patients.14,15 The remaining models were eval-
uated by a team of experts, consisting of a clinical pharmacist, a
What is already known about this subject
• Population pharmacokinetics of vancomycin have been
widely studied in critically ill patients.
• Critically ill patients have severely altered pathophysiol-
ogy, which may lead to differences in pharmacokinetics
of vancomycin with subsequent inadequate drug
concentrations.
• Software using population pharmacokinetic models from
critically ill patients can optimize antibiotic exposure by
accurately predicting dosing requirements for the individ-
ual patient.
What this study adds
• This is the first study to both retrospectively validate and
prospectively evaluate the ability of a pharmacokinetic
model of vancomycin in critically ill patients.
• Predictions of vancomycin concentrations from the best
performing pharmacokinetic model can be made with
acceptable precision for individualized dosing in our
population.
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clinical pharmacologist/clinical pharmacist and a pharmacometrician
for their relevance for practice.
2.2 | Retrospective external evaluation of the
predictive performance of published PK models
The included models were evaluated using retrospective PK data of IC
patients. IC patients with an age of >18 years, receiving vancomycin
(both intermittent and continuous infusion) during their stay in the IC
ward at the Radboudumc University Medical Center (Nijmegen, the
Netherlands) between January 2011 and January 2016 were consid-
ered for inclusion in this retrospective study if at least 1 vancomycin
serum concentration was available. Patients receiving ECMO and/or
dialysis and haemato-oncology patients were excluded for reasons
mentioned above.
The following data were collected from the electronic hospital
system (Epic Systems, Verona, WI, USA): age (y), weight (kg), length
(cm), sex, serum creatinine concentrations (μmol/L), vancomycin dose
(mg), infusion length (h), dosing information (including time of adminis-
tration), plasma vancomycin concentrations (mg/L) and blood sampling
times. Patients with incomplete information were excluded.
The published PK models were evaluated on the retrospectively
collected data. For this purpose, normalized prediction distribution
error (NPDE) plots and visual predictive checks (VPC) were evaluated.
This methodology was previously proposed previously by Zhao
et al.16 to evaluate the transferability of published models to clinical
practice. Lastly, a fit-for-purpose evaluation was performed. For this
purpose, the a priori and a posteriori predictive performance was eval-
uated: meaning their performance before TDM would be performed,
and after 1 or more TDM samples have become available to perform
an individual fit, respectively. Performance was evaluated by calculat-
ing the relative root mean squared error (RRMSE) as measure for pre-
cision and mean prediction error (MPE) as a measure for bias.17 Also,
the individually predicted vs observed concentrations were plotted for
each model for both the a priori and a posteriori situation. The retro-
spective analysis was performed in R v3.5 (R Foundation for Statistical
Computing, Vienna, Austria).
2.3 | Prospective evaluation of the selected PK
model
The best performing model according to judgement of the panel of
experts was carried forward for prospective fit-for-purpose evalua-
tion. In a prospective study, patients with an age of >18 years, receiv-
ing vancomycin (both intermittent and continuous infusion) during
their stay in the IC unit at the Radboudumc University Medical Center
(Nijmegen, the Netherlands), Jeroen Bosch Ziekenhuis (Den Bosch,
the Netherlands), Isala (Zwolle, the Netherlands) and Rijnstate
(Arnhem, the Netherlands) between June 2017 and June 2018 were
considered for inclusion if at least 1 vancomycin serum concentration
available. In all hospitals, sampling of trough concentrations was
implemented as standard of care to guide vancomycin dosing. The
same inclusion and exclusion criteria were applied as were used in the
retrospective evaluation. The data were anonymously recorded in
InsightRX. Dosing of vancomycin was according to local practice and
at the discretion of the treating physician. Both intermittent and con-
tinuous infusions were allowed. Dose adaptations based on TDM
results and InsightRX recommendations were allowed during the
course of treatment.
Predictive performance of the PK model was assessed by calcu-
lating the RRMSE and MPE. We defined an acceptable bias and impre-
cision as <25%, based on the fact that such a bias and imprecision fall
well within the PK trough target that, depending on population, dose
and pathogen, is usually in the range of 10–25 mg/L. For all analyses,
we performed maximum a posteriori Bayesian fitting, without adap-
tive weighting using the InsightRX algorithm.
2.4 | Ethics
The medical ethics committee (Commissie Mensgebonden Onderzoek
Arnhem-Nijmegen, Nijmegen, The Netherlands) waived the necessity
of formal approval and informed consent.
They declared that this research project could be exempted from
obtaining informed consent because all data were obtained during
routine clinical practice and extracted anonymously.
3 | RESULTS
3.1 | Selection of population PK models of
vancomycin in adult patients from literature
A total of 5 suitable population PK models were identified and these
are listed in Table 1. All these models had in common that body
weight was a covariate for the volume of distribution and that esti-
mated creatinine clearance was a covariate for clearance. The disposi-
tion of vancomycin in the body was described with either 1 or
2 compartments.
3.2 | External evaluation of the predictive
performance of published PK models on
retrospectively collected data
Vancomycin data from 30 patients were collected with a median of
3 paired observations of time and vancomycin serum concentrations
(range 2–16). A summary of the data is presented inTable 2.
Figure 1 shows the prediction-corrected VPCs, based on 1,000
simulations on the retrospective data for each model. The blue shaded
areas in this figure show the 95% of the 10th, 50th and 90th of the sim-
ulated data. The lines in the different panels connect the respective
percentiles of the observed data (open circles). As observed, the
models by Zdovc et al.22 Thomson et al.21 and Roberts et al.20 best
TER HEINE ET AL. 2499
described the data, as the observed 10th, 50th and 90th percentiles
(lines) matched the simulated prediction intervals for these percentiles
(blue shaded areas). Furthermore, it can be observed in all plots that
at timepoints >12 hours after last administration all models are under-
predicting. This phenomenon can be explained by the fact that usually
vancomycin in adults is dosed twice or 3 times daily and that because
of TDM dosing intervals are extended to 24 hours. Therefore, at
timepoints later than 12 HOURS, there is a selection bias for data
from patients who have a slower clearance than the population, which
may be misinterpreted as model under-prediction.
Figure 2 shows the QQ-plot of the distribution of the NPDE vs the
theoretical N (0,1) distribution (Figure 2A) as well as the histogram of
the distribution of the NPDE, with the density of the standard Gaussian
distribution overlaid for each model (Figure 2B). It can be seen that the
observed quantiles follow the predicted theoretical quantiles (line of
unity) for most of the data, but curve off at the extreme values. The lat-
ter indicates that the observed PK data have more extreme values than
would be expected if they would come from a normal distribution.
The results of the fit-for-purpose evaluation on the retrospectively
collected data are graphically depicted in Figure 3, showing the MPE as
a measure for bias, the RRMSE as a measure for precision and the
predicted vs observed concentrations in Figure 3A, B and C, respec-
tively. The models by Maarseveen et al.18 Roberts et al.20 Thomson
et al.21 and Zdovc et al.22 performed best on the retrospectively col-
lected data, as observed in the lowest bias and best precision.
3.3 | Model selection and prospective evaluation
Based on overall best performance on the retrospective data, the
model by Thomson et al.21 was implemented in the Insight Rx frame-
work and prospectively evaluated. This decision was based on the
lowest bias and imprecision and the best performance of the VPC,
based on visual assessment.
We included 50 patients in the prospective study. No patients were
excluded from the analysis. Characteristics of the population used for
prospective evaluation of theThomson model are shown inTable 3.
Figure 4A and B show the MPE and overall RRMSE for the a
priori and a posteriori situations with the Thomson model for the pro-
spective evaluation. Figure 4C shows the RRMSE vs the TDM sample.
It can be observed from Figure 4A and B that the accuracy and impre-
cision in the prospectively collected data were improved compared to
retrospectively collected data. Furthermore, it can be observed that
the RRMSE and MPE for the a priori situation are insufficient (>25%),
indicating that vancomycin exposure cannot be adequately predicted
without a previous assessment of the vancomycin plasma concentra-
tion. The bias and imprecision are well below the 25% margin for the
a posteriori situation, indicating suitability for use of the model in clin-
ical practice when the model is used for dose forecasting. Lastly, in
Figure 4C, a trend can be observed that the precision of the prediction
improves when more previous TDM samples are available. Figure 4D
shows the predicted vs the observed concentration. These concentra-
tions are scattered evenly around the line of unity, showing that the
model performs well.
4 | DISCUSSION
We have shown, using a systematic fit-for-purpose evaluation of exis-
ting population PK models for vancomycin in critically ill patients, that
forecasting of vancomycin PK in a critically ill population can be
TABLE 1 Identified population pharmacokinetic models for vancomycin
Model number and authors Population Structural model Covariates
1. van Maarseveen et al.18 Surgical ward patients, internal ward patients
and critically ill patients (number of patients
for model development not reported)
1 compartment Total body weight on volume of distribution
Creatinine clearance of clearance of vancomycin
2. Llopis-Salvia et al.19 Critically ill patients (n = 30) 2 compartments Total body weight on volume of distribution
Creatinine clearance of clearance of vancomycin
3. Roberts et al.20 Critically ill patients (n = 206) 1 compartment Total body weight on volume of distribution
Creatinine clearance of clearance of vancomycin
4. Thomson et al.21 Hospitalized patients, independent of
condition (n = 398)
2 compartments Total body weight on volume of distribution
Creatinine clearance of clearance of vancomycin
5. Zdovc et al.22 Critically ill patients (n = 33) 1 compartment Total body weight on volume of distribution
Creatinine clearance of clearance of vancomycin





Age, median (range) 59 (20–82) y
Weight, median (range) 80 (54–133) kg
Height, median (range) 1.72 (1.37–1.90) m
Serum creatinine, median (range) 84 (40–189) μmol/L
Number of observations per patient, median
(range)
3 (2–16)
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performed accurately and precisely based on an existing PK model
and routinely measured vancomycin concentrations. The predictive
performance of the evaluated models was insufficient to dose vanco-
mycin in this population without assessment of vancomycin plasma
concentrations, underlining the necessity of TDM of vancomycin in
critically ill patients.
The analysis described here is the first prospective evaluation of
an MIPD tool for vancomycin in critically ill patients. We found that
the model by Thomson et al.21 performed best in a retrospective eval-
uation and then showed in a prospective multicentre study that it
could precisely and accurately predict vancomycin exposure. It
could be observed that the predictive performance in the prospective
evaluation was better than in the retrospective evaluation. It is most
likely that this is a result of the better quality of prospectively col-
lected data and this shows the usefulness of a prospective evaluation.
We found a small bias in the a posteriori predictive performance
(MPE of 8.84%). We think this structural bias is negligible compared
to the therapeutic window, that is usually in the range of
10–25 mg/L. Therefore, dose advices should always be verified with
follow-up measurements of the vancomycin serum concentration.
Furthermore, in both the retrospective and prospective evalua-
tion, it could be observed that for the a priori situation, the situation
where vancomycin PK are only predicted based on covariates and
dose, the predictive performance was poor. This underlines the cur-
rent consensus that vancomycin dosing should be guided by TDM.
Guo et al.23 recently performed a retrospective evaluation of the
predictive performance of several population PK models for vancomy-
cin in 2 Dutch hospitals. It was concluded that, on a population level,
the model by Roberts et al.20 performed satisfactorily. These results
are in line with our retrospective results, where the model by Roberts
et al.20 performed adequately. Unfortunately, Guo et al. did not evalu-
ate the model by Thomson et al.21 Furthermore, a prospective fit-for-
purpose evaluation13 was lacking in the analysis by Guo et al.23 to
evaluate how well vancomycin exposure could be predicted from a
previous PK assessment. A fit-for-purpose evaluation of various popu-
lation PK models for vancomycin in adult patients was recently also
performed by Broeker et al.24 This study performed a similar evalua-
tion as performed by us, albeit in a retrospective setting. The strength
of the analysis by Broeker et al. is that a cross-sectional evaluation
was performed in a general hospital population. This may, however,
F IGURE 1 Visual predictive checks
of the identified models on the
retrospective data. The blue shaded areas
in this figure show the 95% of the 10th,
50th and 90th of the simulated data. The
lines in the different panels connect the
respective percentiles of the observed
data (open circles)
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also be a limitation, as it is known that some populations, such as criti-
cally ill25 or neutropenic26 patients, exhibit altered vancomycin
PK. We therefore postulate that our prospective fit-for-purpose eval-
uation in the critically ill population is of added value.
As the ultimate goal of MIPD of vancomycin is to forecast the
dose based on previous vancomycin PK observations, we performed a
prospective multicentre study where we evaluated the individual pre-
dictive performance of the model by Thomson et al.21 to predict
F IGURE 2 QQ-plot of the distribution of the normalized prediction distribution error (NPDE) vs the theoretical N (0,1) distribution (A) as well
as the histogram of the distribution of the NPDE, with the density of the standard N(0,1) distribution overlaid for each model (B). It can be seen
that the observed quantiles seem to follow a normal distribution, but are more dispersed than the theoretical N(0,1) distribution
2502 TER HEINE ET AL.
F IGURE 3 (A) Mean prediction error (MPE) including 95% confidence intervals obtained with the various models on the retrospective data.
(B) Relative root mean squared error (RRMSE) including 95% confidence intervals obtained with the various models on the retrospective data.
(C) Predicted vs observed concentrations obtained with the various models on the retrospective data
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future vancomycin PK from a previous observation of its PK, dose and
covariates.
One may argue that a shortcoming of our analysis is that the pri-
mary endpoint of our prospective fit-for-purpose evaluation is a
numerical outcome, and not a clinical outcome such as time-to-cure
or time-to-therapeutic target attainment. We have chosen the current
endpoint as multimorbidity and high variable vancomycin PK in criti-
cally ill patients, as well as differences in local TDM practice in the
participating centres may all blur these outcomes.
Furthermore, a shortcoming of our study is that we did not
include patients on haemodialysis, continuous venovenous
haemofiltration or ECMO in our study. A next step in MIPD of vanco-
mycin in the critically ill population should, therefore, be development
and prospective validation of PK models that can adequately capture
vancomycin PK for these patients as well, despite the potential
limitations.27 Until then, we advise to perform intensified PK monitor-
ing of vancomycin when dialysis techniques or ECMO are used to pre-
vent inadequate therapy.
Although practice guidelines currently advocate the use of trough
levels to guide vancomycin dosing,4 there is increasing evidence that
the AUC is a better surrogate endpoint for efficacy than trough con-
centrations and that using trough levels alone to guide vancomycin
dosing should be reconsidered.28 The purpose of our evaluation was
to prospectively evaluate the predictive performance of model-based
TDM in a multicentre study, where trough sampling was implemented
as standard of care. It should be noted that, if the AUC has to be
predicted from a previous PK assessment, one should first establish a
sampling schedule for reliable assessment of AUC and then evaluate
the predictive performance of this scheme for purpose of MIPD. This
was, however, not the purpose of our analysis, where we evaluated
the predictive performance various model for prediction of subse-
quent trough concentrations of vancomycin. As stated earlier, the
therapeutic window for vancomycin depends on both the dosing regi-
men, exposure-related toxicity and the pathogen susceptibility. The
predictive performance of the used MIPD strategy should always be
put in context with the therapeutic window and it should be noted
that the therapeutic window for vancomycin may become small with
pathogens with reduced vancomycin susceptibility. It is, therefore,
advisable to always verify the MIPD intervention with a follow-up PK
assessment. Furthermore, if of vancomycin the AUC24/MIC target is
used for MIPD, sources of variability in the assessment of both the
AUC24 as the MIC should be considered.29
In conclusion, we have systematically evaluated the fitness of var-
ious model for use of MIPD of vancomycin in critically ill patients. The
TABLE 3 Population characteristics




Age, median (range) 68 (36–84) y
Weight, median (range) 82 (50–110) kg
Height median (range) 1.72 (1.57–1.93) m
Serum creatinine median (range) 79 (73–285) μmol/L
Number of observations per patient, median
(range)
4 (1–23)
F IGURE 4 (A) Mean prediction error (MPE) including 95% confidence intervals in the prospective study. (B) Relative root mean squared error
(RRMSE) including 95% confidence intervals in the prospective study. (C) Relative root mean squared error vs therapeutic drug monitoring (TDM)
sample in the prospective study. (D) Predicted vs observed concentrations in the prospective study
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model by Thomson et al.21 is now used in clinical practice for this pur-
pose. Our approach, using a retrospective evaluation and prospective
verification, may be used for evaluation of models for other drugs and
populations.
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